Biotech Values

[jawwx3]

Early approval will likely be for the unmet need of treatment failure patients. Telaprevir is clearly better than boceprevir in treatment failure patients. I think telaprevir and boceprevir both work, which only makes it more clear to the fda that one of them should get early approval, telaprevir is the better choice for early approval for treatment failure patients. Remember, there are 300,000 and 9000 a year are dying.